Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

A guide to the people and activist organizations who paved the way for Donald Trump's attacks on diversity practices in ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

LANSING, MI — Pharmaceutical giant Pfizer has agreed to pay $59.7 million plus interest to settle bribery allegations against ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...